<DOC>
	<DOCNO>NCT01259817</DOCNO>
	<brief_summary>The aim research look two condition , Essential Thrombocythemia ( ET ) Polycythemia Vera ( PV ) . ET cause people produce many blood cell call platelet PV cause many platelet red blood cell make . Platelets particles circulate blood stream normally prevent bleed bruising . Having many platelet blood increase risk develop blood clot , result life threaten event like heart attack stroke . When number red blood cell increase PV slow speed blood flow body increase risk develop blood clot . It important patient ET PV risk blood clot receive drug minimize risk develop blood clot moment investigator sure drug best control disorder . The purpose study look effectiveness give patient diagnose ET PV study drug regimen use Aspirin PEGASYS ( also know Pegylated interferon alfa-2a , instead standard treatment drug call Hydroxyurea ( hydroxycarbamide Hydroxyurea ) , drug may suitable . The drug may suitable either adequately control number blood cell specific side effect occur .</brief_summary>
	<brief_title>Pegylated Interferon Alfa-2a Salvage Therapy High Risk Polycythemia Vera ( PV ) Essential Thrombocythemia ( ET )</brief_title>
	<detailed_description>Myeloproliferative disorder ( MPDs ) clonal hematologic disease characterize excess production one lineages mature blood cell , predisposition bleed thrombotic complication , extramedullary hematopoiesis , variable progression acute leukemia . The classical Philadelphia chromosome-negative MPDs polycythemia vera ( PV ) , characterized expansion red blood cell production ; essential thrombocythemia ( ET ) , characterize isolated elevation platelet count ; myelofibrosis , distinguish fibrotic bone marrow peripheral blood cytopenia , accompany high risk leukemic transformation . Myelofibrosis arise de novo , primary myelofibrosis ( PMF ) , evolve PV ET diseases progress ( call post-PV MF post-ET MF ) . Amongst MPDs , characterize myelofibrosis ( PMF together post-PV post-ET MF ) carry bad prognosis , median survival order 3 5 year . Patients typically present anemia , often require transfusion , symptomatic splenomegaly severe constitutional symptom . Donor stem cell transplantation potentially curative therapy . To date therapy myelofibrosis show offer survival benefit , therapy myelofibrosis palliative . In 2005 , major breakthrough understand pathophysiology MPDs come 4 group describe recurrent somatic mutation Janus kinase 2 ( JAK2 ) majority patient MPDs . The point mutation JAK2 encode valine phenylalanine change position 617 ( JAK2 V617F ) , confers constitutive tyrosine kinase activity . Introducing mutation bone marrow mouse model recapitulate PV phenotype ( complete evolution bone marrow fibrosis ) inhibitor JAK2 attenuate growth cell line bear mutation vitro vivo , suggest JAK2 V617F pathophysiologically relevant therapeutic target . It estimate 95 % PV case carry JAK2 V617F , 50 60 % ET PMF case JAK2 V617F+ . The discovery JAK2V617F mutation nearly patient PV half ET PMF redefine classification possibly management MPNs . Despite discovery JAK2V617F mutation , many clinical question management MPNs remain unanswered . In PV , example , cardiovascular mortality remain 1.4 1.6 time reference normal population leukemia myelofibrosis rate many time increase baseline . Debate continue role venesection versus cytoreduction first-line therapy , whether hydroxycarbamide ( Hydroxyurea ) associate well thrombotic prophylaxis and/or high rate leukemic transformation . Interferons may produce molecular response PV patient . In high-risk ET , Hydroxyurea aspirin appear optimal anagrelide aspirin , vascular complication remain significant cause mortality morbidity , suggest target vascular risk factor may worthwhile . Furthermore Hydroxyurea regard first-choice therapy high risk patient ET PV ; 10 % patient attain desired reduction platelet number hematocrit recommend dose drug , exhibit clinical resistance , whereas develop unacceptable side effect , demonstrate clinical intolerance . Quantitation JAK2V617F allele burden provide first time opportunity monitor effect potential therapeutic agent malignant clone patient PV . Great enthusiasm express use small molecule inhibitor JAK2 treatment patient MPN . Phase 1/2 trial indicate great expect toxicity , non specificity action inability compound dramatically alter JAK2V617F allele burden . Interferon ( rIFN -2b ) , drug appear non-leukemogenic ( contrary 32P , alkylating agent , possibly Hydroxyurea ) , may preferential activity malignant clone PV , suggest cytogenetic remission obtain patient treated rIFN -2b . This trial design open-label phase 2 study conduct two stratum patient high risk PV ET intolerant hydroxyurea . Patients ET PV Splanchnic Vein Thrombosis ( regardless prior hydroxyurea ) enrol separate stratum .</detailed_description>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>A diagnosis ET PV shall make accordance WHO ( 2008 ) criterion ( Swerdlow 2008 ) show ( Values time diagnosis , study entry ) : Polycythemia Vera ( 2 major criterion require ) 1 . Hb &gt; 18.5g/dl ( ♂ ) 16.5g/dl ( ♀ ) HCT &gt; 99 percentile reference range Elevated red cell mass ( &gt; 25 % mean predict value ) Hb &gt; 17g/dl ( ♂ ) 15g/dl ( ♀ ) associate sustained rise baseline apparent cause ( e.g . treat iron deficiency ) . 2 . Presence JAK2V617F If source documentation diagnostic criterion # 1 obtain , diagnosis make ( 1 ) addition erythropoietin level reference range normal AND ( 2 ) bone marrow biopsy show hypercellularity age trilineage ( panmyelosis ) prominent erythroid , granulocytic , megakaryocytic proliferation . Essential Thrombocythemia ( 6 criterion require ) 1 . Platelets count ≥ 450 x 10 9/L 2 . Megakaryocyte proliferation large mature morphology . No little granulocyte erythroid proliferation . Patients may include 2+ marrow reticulin fibrosis . 3 . Not meet WHO criterion CML , PV , MDS , PMF myeloid neoplasm 4 . Demonstration clonal cytogenetic marker evidence reactive thrombocytosis . 5 . Absence leukoerythroblastic blood picture . 6 . May participate study without presence JAK2V617F . Patients must high risk disease define : High risk PV ANY ONE following : Age ≥ 60 year Previous document thrombosis , erythromelalgia migraine ( severe , recurrent , require medication , felt secondary MPN ) either diagnosis within 10 year diagnosis consider disease relate Significant ( i.e . ≥ 5cm costal margin palpation ) symptomatic splenomegaly ( splenic infarct require analgesia ) Platelets ≥ 1000 x 10 9/L Diabetes hypertension require pharmacological therapy ≥ 6 month High risk ET ANY ONE following : Age ≥ 60 year Platelet count ≥ 1500 x 10 9/L Previous document thrombosis , erythromelalgia migraine ( severe , recurrent , require medication , felt secondary MPN ) either diagnosis within 10 year diagnosis consider disease relate Previous hemorrhage relate ET Diabetes hypertension require pharmacological therapy ≥ 6 month In addition patient must EITHER intolerant resistant Hydroxyurea accord establish criterion follow : Any ONE following : Platelet count ≥ 600 x 10 9/L 3 month least 2 g/day Hydroxyurea ( 2.5 g/day patient body weight &gt; 80 kg ) WBC &lt; 2.5 x 109/L Hgb &lt; 11g/dl dose hydroxyurea exceed 2g/day . Progressive splenomegaly hepatomegaly ( &gt; 5cm initiation hydroxyurea ) appearance new splenomegaly hepatomegaly MTD hydroxyurea . Not achieve Hct &lt; 45 % order eliminate need supplemental phlebotomy 3 month least 2g/day MTD hydroxyurea . Not achieve WBC &lt; 10 x 109/L 3 month least 2g/day MTD hydroxyurea . Having platelet count &lt; 100 x 109/L hydroxyurea dose without eliminate need supplemental phlebotomy progressive splenomegaly define . Development major thrombotic episode ( CVA , myocardial infarction , severe migraine require medication , abdominal vein thrombosis , deep vein thrombosis ) treat maximal tolerated dos hydroxyurea . Presence leg ulcer unacceptable Hydroxyurearelated nonhematological toxicity , unacceptable mucocutaneous manifestation , gastrointestinal symptom , pneumonitis fever dose Hydroxyurea . OR Splanchnic Vein Thrombosis ( SVT ) ( include BuddChiari , abdominal vein thrombosis , portal vein thrombosis , splenic vein thrombosis ) . For patient follow additional inclusion/exclusion criterion apply : &gt; 3 month since onset SVT SVT treat oral anticoagulant aspirin Liver enzymes &gt; 2 time normal value Absence encephalopathy , refractory infect ascites , esophageal varicose grade &gt; 1 time trial entry Bone marrow biopsy confirm diagnosis PV ET JAK2V617F mutation present These patient may normal blood count trial entry Age 18 year ( upper age limit ) Able willing comply study criterion Signed informed consent participant study Willing participate associate correlative science biomarker study Serum creatinine &lt; 1.5 x upper limit normal AST ALT &lt; 2 x upper limit normal Total bilirubin within normal limit Patients form chemotherapy MPD ( hydroxyurea ) . Specifically prior interferon JAK2 inhibitor prohibit . If patient receive prior hydroxyurea , taper hydroxyurea period first 2 month Pegylated interferon alfa2a therapy . Taper treat physician 's discretion , must absent ( complete ) start third month . Patients prior malignancy within last 5 year ( except basal squamous cell carcinoma , situ cancer cervix ) Presence lifethreatening comorbidity History active substance alcohol abuse within last year Any contraindication pegylated nonpegylated interferon Subjects positive pregnancy test , pregnant , lactate reproductive potential practicing effective mean contraception History psychiatric disorder ( e.g . depression ; suicidal ideation ; psychosis ) Subjects history mild depression may consider entry study , provide pretreatment assessment subject 's affective status support subject clinically stable base investigator 's normal practice subject . History autoimmune disorder ( e.g . hepatitis ; ITP ; scleroderma ; severe psoriasis affect &gt; 10 % body , rheumatoid arthritis require intermittent NSAID management ) Hypersensitivity IFNα HBV untreated systemic infection Known HIV disease Evidence severe retinopathy ( e.g . CMV retinitis , macular degeneration ) clinically relevant ophthalmological disorder ( e.g . due diabetes mellitus hypertension ) History evidence decompensated liver disease History evidence chronic pulmonary disease associate functional limitation Thyroid dysfunction adequately control Any investigational drug &lt; 6 week prior first dose study drug recover effect prior investigational agent . Presence JAK2 exon 12 mutation Patients meet criterion post PV post ETMF ( see appendix B ) Previous exposure formulation interferon Subjects medical condition , opinion investigator would compromise result study deleterious effect treatment . History major organ transplantation History uncontrolled severe seizure disorder Inability give inform write consent Serum creatinine &gt; 1.5 x upper limit normal AST ALT &gt; 2 x upper limit normal Total bilirubin &gt; 1.5 mg/ml No detectable PNH ( paroxysmal nocturnal hemoglobinuria ) clone test Concurrent hormonal contraceptive use</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Polycythemia Vera</keyword>
	<keyword>Essential Thrombocythemia</keyword>
	<keyword>Hydroxyurea Resistant</keyword>
	<keyword>Abdominal Vein Thrombosis</keyword>
	<keyword>PEGASYS</keyword>
</DOC>